Randomized trial · people

Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this Japanese trial, dulaglutide 0.75 mg lowered blood sugar but did little to body weight, and tirzepatide lowered both more, with more nausea.

Kind
Randomized trial
Studied in
People
Number studied
636
Published
2022
Journal
Lancet Diabetes Endocrinol

What they tested

The team tested whether weekly tirzepatide at 5, 10 or 15 mg controlled blood sugar and body weight better than weekly dulaglutide 0.75 mg in Japanese people with type 2 diabetes.

How the study was done

A double-blind (neither patients nor doctors knew who got which drug), randomized, phase 3 trial at 46 centers in Japan in 636 adults with type 2 diabetes who were new to treatment or had stopped a single oral diabetes drug. Equal-sized groups got one of four weekly shots for 52 weeks: dulaglutide at 0.75 mg, or tirzepatide at a dose of 5 mg, 10 mg or 15 mg.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 52, HbA1c (a 3-month average of blood sugar) fell by 1.3 in the dulaglutide arm, compared with 2.4, 2.6 and 2.8 in the tirzepatide 5, 10 and 15 mg arms. Against dulaglutide, the extra drop with tirzepatide ranged from 1.1 to 1.5 (all p<0.0001). Body weight changed by -0.5 kg (-0.7%) with dulaglutide, versus -5.8 kg, -8.5 kg and -10.7 kg (-7.8%, -11.0% and -13.9%) across the tirzepatide arms. Nausea affected 8% of the dulaglutide group and 12% to 20% of the tirzepatide groups; constipation affected 11% versus 14% to 18%.

What it doesn’t show

Dulaglutide was tested only at 0.75 mg, and the trial included only Japanese adults, about three quarters of them men, for 52 weeks. It was funded by Eli Lilly and Company.

The paper

Inagaki et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022.

The compounds

More studies on Dulaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking dulaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo